Drucker Wealth 3.0 LLC Grows Stock Holdings in Johnson & Johnson $JNJ

Drucker Wealth 3.0 LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 121.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,419 shares of the company’s stock after buying an additional 7,348 shares during the period. Drucker Wealth 3.0 LLC’s holdings in Johnson & Johnson were worth $2,097,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of JNJ. Brighton Jones LLC grew its position in shares of Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after purchasing an additional 6,332 shares in the last quarter. Wealth Group Ltd. purchased a new position in shares of Johnson & Johnson during the 1st quarter valued at $218,000. GAMMA Investing LLC grew its position in shares of Johnson & Johnson by 48.0% during the 1st quarter. GAMMA Investing LLC now owns 43,508 shares of the company’s stock valued at $7,215,000 after purchasing an additional 14,118 shares in the last quarter. ShankerValleau Wealth Advisors Inc. purchased a new position in shares of Johnson & Johnson during the 1st quarter valued at $202,000. Finally, Azzad Asset Management Inc. ADV purchased a new position in shares of Johnson & Johnson during the 1st quarter valued at $6,351,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on JNJ. Wells Fargo & Company set a $212.00 price target on shares of Johnson & Johnson and gave the company an “overweight” rating in a research report on Friday, October 3rd. UBS Group set a $198.00 price objective on shares of Johnson & Johnson in a report on Friday, October 3rd. Citigroup lifted their price objective on shares of Johnson & Johnson from $200.00 to $213.00 and gave the stock a “buy” rating in a report on Tuesday, October 7th. Bank of America lifted their price objective on shares of Johnson & Johnson from $175.00 to $198.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Finally, Wall Street Zen raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $192.94.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $190.66 on Monday. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The company has a market capitalization of $459.16 billion, a PE ratio of 20.39, a P/E/G ratio of 2.40 and a beta of 0.40. The firm has a fifty day simple moving average of $178.48 and a two-hundred day simple moving average of $163.78. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $192.10.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. Research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were given a $1.30 dividend. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. Johnson & Johnson’s payout ratio is presently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.